Repligen Corporation (RGEN) is listed on NASDAQ in Biotech Stocks. It is $176.24, -3.18%, with a $9.9B market cap. RSI is 62.2, near overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 62.2 Near Overbought
Market Cap $9.9B
Volume 647.0K
Fundamentals — 10-Q Q2 2026
Revenue --
Net Income $13.3M
EPS $0.24
Debt / Equity 0.3x
P/E Ratio 734.3x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer | Sell | 5,426 | $180.00 | $976,680 | 2026 Aug 20 |
| Garland Jason K | CFO | Sell | 530 | $150.00 | $79,500 | 2026 Jul 16 |
| Garland Jason K | CFO | Sell | 733 | $145.00 | $106,285 | 2026 Jun 25 |
| Loeillot Olivier | Chief Executive Officer | Sell | 3,832 | $140.00 | $536,480 | 2026 Apr 21 |
| Dawes Karen A | Director | Sell | 275 | $161.00 | $44,275 | 2025 Dec 17 |
| Loeillot Olivier | Chief Executive Officer | Sell | 7,041 | $170.00 | $1.2M | 2025 Nov 25 |
| Bylund James | Chief Operating Officer | Sell | 2,191 | $151.21 | $331,301 | 2025 Nov 18 |
| Hunt Anthony | Director | Sell | 20,000 | $154.61 | $3.1M | 2025 Nov 13 |
| Hunt Anthony | Director | Sell | 25,000 | $156.88 | $3.9M | 2025 Nov 12 |
| Hunt Anthony | Director | Sell | 29,111 | $120.52 | $3.5M | 2025 Sep 10 |
| Madaus Martin D | Director | Buy | 1,800 | $112.13 | $201,834 | 2025 Aug 8 |
| Hunt Anthony | Director | Sell | 26,447 | $123.71 | $3.3M | 2025 May 15 |
| Hunt Anthony | Director | Sell | 26,756 | $152.51 | $4.1M | 2025 Mar 17 |
| Pax Margaret | Director | Buy | 250 | $150.69 | $37,673 | 2025 Mar 17 |
| Hunt Anthony | Director | Sell | 24,246 | $139.67 | $3.4M | 2024 Nov 21 |
| Hunt Anthony | Director | Sell | 22,191 | $145.37 | $3.2M | 2024 Sep 10 |
| Kuriyel Ralf | Senior VP, R&D | Sell | 7,148 | $159.35 | $1.1M | 2024 Aug 2 |
| Kuriyel Ralf | Senior VP, R&D | Sell | 4,465 | $165.67 | $739,717 | 2024 Aug 1 |
| Barthelemy Nicolas | Director | Buy | 1,200 | $125.45 | $150,540 | 2024 Jun 14 |
| Hunt Anthony | Chief Executive Officer | Buy | 2,000 | $124.08 | $248,160 | 2024 Jun 14 |
Other Biotech Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $137.93 | 63.6 | $55.1B |
| | $432.33 | 66.2 | $233.7B |
| | $145.64 | 60.3 | $180.6B |
| | $8.05 | 54.2 | $8.5B |
| | $218.46 | 60.5 | $32.3B |
| | $54.45 | 50.2 | $13.5B |
| | $153.99 | 40.2 | $15.7B |
| | $118.23 | 51.7 | $9.8B |
Take RGEN further
- Browse Biotech Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put RGEN in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Repligen Corporation next reports.
Set alerts on RGEN
Get notified when Repligen Corporation hits your price targets or technical conditions are met.
Get Started Free